scholarly journals PREVALENCE OF KLEBSIELLA PNEUMONIAE CAUSING VENTILATOR-ASSOCIATED PNEUMONIA (VAP) ISOLATED FROM PEDIATRIC INTENSIVE CARE UNIT AT ASSIUT UNIVERSITY HOSPITAL

2017 ◽  
Vol 40 (1) ◽  
pp. 49-56
Author(s):  
Eman Mohamed ◽  
Hamada Mohamed ◽  
Sherine Abd El- Rahman ◽  
Shabaan Hashem
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Klebsiella Pneumoniae ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
University Hospital ◽  
Ventilator Associated Pneumonia

Interprofessional Approach to the Sustained Reduction in Ventilator-Associated Pneumonia in a Pediatric Intensive Care Unit

2018 ◽  
Vol 38 (6) ◽  
pp. 36-45 ◽  
Author(s):  
Cheryl Lynne McBeth ◽  
Rosa Solis Montes ◽  
Amy Powne ◽  
Sopon Elizabeth North ◽  
JoAnne E. Natale
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Ventilator Associated Pneumonia ◽  
Sustained Reduction

Study of fungal infections in pediatric intensive care unit in Menoufiya University Hospital

2014 ◽  
Vol 27 (1) ◽  
pp. 55
Author(s):  
NagwanY. Saleh ◽  
FadyM. ElGendy ◽  
FahimaM. Hassan ◽  
AhmedA. Khatab ◽  
GhadaR. El-Hendawy
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Fungal Infections ◽  
Pediatric Intensive Care ◽  
University Hospital

scholarly journals Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Maria Cristina Mondardini ◽  
Francesca Sperotto ◽  
Marco Daverio ◽  
Fabio Caramelli ◽  
Dario Gregori ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Withdrawal Syndrome ◽  
Clinical Signs ◽  
Pediatric Intensive Care ◽  
University Hospital ◽  
Prolonged Treatment ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background Prolonged treatment with analgesic and sedative drugs in the pediatric intensive care unit (PICU) may lead to undesirable effects such as dependence and tolerance. Moreover, during analgosedation weaning, patients may develop clinical signs of withdrawal, known as withdrawal syndrome (WS). Some studies indicate that dexmedetomidine, a selective α2-adrenoceptor agonist, may be useful to prevent WS, but no clear evidence supports these data. The aims of the present study are to evaluate the efficacy of dexmedetomidine in reducing the occurrence of WS during analgosedation weaning, and to clearly assess its safety. Methods We will perform an adaptive, multicenter, randomized, double-blind, placebo-controlled trial. Patients aged < 18 years receiving continuous intravenous analgosedation treatment for at least 5 days and presenting with clinical conditions that allow analgosedation weaning will be randomly assigned to treatment A (dexmedetomidine) or treatment B (placebo). The treatment will be started 24 h before the analgosedation weaning at 0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h (neonate: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h) and continued throughout the whole weaning time. The primary endpoint is the efficacy of the treatment, defined by the reduction in the WS rate among patients treated with dexmedetomidine compared with patients treated with placebo. Safety will be assessed by collecting any potentially related adverse event. The sample size assuring a power of 90% is 77 patients for each group (total N = 154 patients). The study was approved by the Ethics Committee of the University-Hospital S.Orsola-Malpighi of Bologna on 22 March 2017. Discussion The present trial will allow us to clearly assess the efficacy of dexmedetomidine in reducing the occurrence of WS during weaning from analgosedation drugs. In addition, the study will provide a unique insight into the safety profile of dexmedetomidine. Trial registration ClinicalTrials.gov, NCT03645603. Registered on 24 August 2018. EudraCT, 2015–002114-80. Retrospectively registered on 2 January 2019.

scholarly journals Ventilator-Associated Pneumonia in Neonatal and Pediatric Intensive Care Unit Patients

2007 ◽  
Vol 20 (3) ◽  
pp. 409-425 ◽  
Author(s):  
Elizabeth Foglia ◽  
Mary Dawn Meier ◽  
Alexis Elward
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Antibiotic Use ◽  
Educational Interventions ◽  
Empiric Therapy ◽  
Attributable Mortality ◽  
Ventilator Associated Pneumonia ◽  
Case Control Studies

SUMMARY Ventilator-associated pneumonia (VAP) is the second most common hospital-acquired infection among pediatric intensive care unit (ICU) patients. Empiric therapy for VAP accounts for approximately 50% of antibiotic use in pediatric ICUs. VAP is associated with an excess of 3 days of mechanical ventilation among pediatric cardiothoracic surgery patients. The attributable mortality and excess length of ICU stay for patients with VAP have not been defined in matched case control studies. VAP is associated with an estimated $30,000 in attributable cost. Surveillance for VAP is complex and usually performed using clinical definitions established by the CDC. Invasive testing via bronchoalveolar lavage increases the sensitivity and specificity of the diagnosis. The pathogenesis in children is poorly understood, but several prospective cohort studies suggest that aspiration and immunodeficiency are risk factors. Educational interventions and efforts to improve adherence to hand hygiene for children have been associated with decreased VAP rates. Studies of antibiotic cycling in pediatric patients have not consistently shown this measure to prevent colonization with multidrug-resistant gram-negative rods. More consistent and precise approaches to the diagnosis of pediatric VAP are needed to better define the attributable morbidity and mortality, pathophysiology, and appropriate interventions to prevent this disease.

Ventilator-Associated Pneumonia in the Pediatric Intensive Care Unit: Characterizing the Problem and Implementing a Sustainable Solution

2009 ◽  
Vol 154 (4) ◽  
pp. 582-587.e2 ◽  
Author(s):  
Michael T. Bigham ◽  
Rick Amato ◽  
Pattie Bondurrant ◽  
Jon Fridriksson ◽  
Catherine D. Krawczeski ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Ventilator Associated Pneumonia
Sign in / Sign up

Export Citation Format

Share Document